Список проголосовавших за комментарий " On The Wires<ul><li>Aurinia Pharmaceuticals Inc. (<strong>AUPH</strong>) announced that it has selected Worldwide Clinical Trials («Worldwide») as its Clinical Research Organization (CRO) for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis (LN).</li><li>Mitsubishi Tanaba Pharma announced that Biogen (<strong>BIIB</strong>) and the company reached an agreement to terminate the license agreement for MT-1303, a therapeutic agent for autoimmune diseases, discovered and developed by Mitsubishi Tanaba. In Otober, Biogen announced it would discontinue its development plan for MT-1303 due to its strategic objectives.</li><li>Knight Therapeutics announced that it has acquired 6,200,000 common shares of Israeli based Protalix BioTherapeutics (<strong>PLX</strong>) at an average price of $0.57 per share. Knight now owns approximately 5% of the outstanding common shares of Protalix. Knight acquired the Shares for investment purposes.</li></ul>"